Sai Parenteral's
Sai Parenteral's Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #77 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Sai Parenteral's Q4 FY26 key numbers
- Revenue
- Full operationalization of ongoing INR 440 crores capex projects expected by end of FY '27, with revenue impact beginning FY '28.
As stated in Sai Parenteral's's Q4 FY26 earnings call transcript · published 25 Aug 2026. Reported figures, not investment advice.
The short version
FY '27 revenue guidance is INR 750 crores, reflecting a conservative estimate due to typical H1-H2 seasonality (40%-60% split). FY 27 is an execution year with a targeted revenue of INR 750 crores and EBITDA margin of 17%.
From Sai Parenteral's's Q4 FY26 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- FY '27 revenue guidance is INR 750 crores, reflecting a conservative estimate due to typical H1-H2 seasonality (40%-60% split).
- FY '27 targets 17% EBITDA margin, up from ~14.6% in Q4 FY '26, driven by vertical integration and manufacturing shifts.
- Full operationalization of ongoing INR 440 crores capex projects expected by end of FY '27, with revenue impact beginning FY '28.
- FY '28 anticipated as a ramp-up year with contributions from new Australian facility, expanded capacities, EU-GMP upgrades, and R&D center.
- Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets.
- 67 dossiers under development at Sai to be commercialized in FY '27 and FY '28, enhancing future sales visibility.
2 more points from Sai Parenteral's's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sai Parenteral's said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Sai Parenterals is executing a INR440 crores growth capex program focused on capacity expansion and upgradation in India and Australia, plus a new dedicated R&D center.
- INR110 crores capex in India for capacity expansion and EU-GMP upgrades at manufacturing facilities, fully funded by IPO proceeds.
- INR15 crores investment towards establishing the R&D center in India, also funded through IPO proceeds.
- Australian entity Noumed facility expansion involves a total planned capex of AUD 53 million (INR311 crores), with AUD 20 million grant from the Australian government.
- AUD 40 million invested so far in the Australian project, funded through a mix of debt and internal accruals.
2 more points from Sai Parenteral's's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sai Parenteral's said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Sai Parenteral's's call on order book
Create a free account to keep reading this call
Sai Parenteral's — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹198 Cr, net profit ₹13 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sai Parenterals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharmaceuticals Ltd (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals Ltd (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sai Parenteral's and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sai Parenteral's Q4 FY26 results?
FY '27 revenue guidance is INR 750 crores, reflecting a conservative estimate due to typical H1-H2 seasonality (40%-60% split). FY 27 is an execution year with a targeted revenue of INR 750 crores and EBITDA margin of 17%.
What is Sai Parenteral's share price analysis?
Sai Parenteral's currently shows a neutral. The stock trades at a P/E of 115.1 with a market cap of ₹2,389 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sai Parenteral's planning capital expenditure?
Sai Parenterals is executing a INR440 crores growth capex program focused on capacity expansion and upgradation in India and Australia, plus a new dedicated R&D center.
Keep Sai Parenteral's on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.